---
title: "Caribou Biosciences: Buy Rating Reaffirmed on Advancing Allogeneic CAR-T Pipeline and EHA Data; $6 Price Target Maintained"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289533892.md"
description: "Bank of America analyst Alec Stranahan reaffirmed a Buy rating on Caribou Biosciences with a $6 price target. The decision cites advancing allogeneic CAR-T pipeline data, including robust vispa-cel results in large B-cell lymphoma and promising CB-011 outcomes in multiple myeloma presented at EHA. Stranahan highlights the potential for outpatient use and durable responses, suggesting the stock's current discount may narrow as clinical execution is validated."
datetime: "2026-06-12T00:19:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289533892.md)
  - [en](https://longbridge.com/en/news/289533892.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289533892.md)
generator: "portal-rs"
---

# Caribou Biosciences: Buy Rating Reaffirmed on Advancing Allogeneic CAR-T Pipeline and EHA Data; $6 Price Target Maintained

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Caribou Biosciences yesterday and set a price target of $6.00.

### Introducing TipRanks MCP for Agents

-   Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
-   Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.

Alec Stranahan has given his Buy rating due to a combination of factors tied to Caribou’s advancing allogeneic CAR-T portfolio and the encouraging updates presented at EHA. The latest vispa-cel data in second-line large B-cell lymphoma show robust response rates, extended progression-free survival, and a safety profile that appears suitable for outpatient and community-center use, supporting a credible path toward pivotal execution.

At the same time, CB-011 continues to demonstrate deep and durable responses in heavily pretreated, BCMA-naïve multiple myeloma patients, with early signals that may also be relevant for BCMA-exposed settings as data mature. With a clear pivotal trial framework for vispa-cel, upcoming catalysts at EHA and beyond, and unchanged upside to the $6 price objective from a $1.79 share price, Stranahan sees room for the stock’s current discount to narrow as execution and clinical durability are further validated.

### Related Stocks

- [CRBU.US](https://longbridge.com/en/quote/CRBU.US.md)
- [BAC.US](https://longbridge.com/en/quote/BAC.US.md)
- [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md)
- [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md)
- [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md)
- [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md)
- [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md)
- [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md)
- [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md)
- [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md)
- [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md)
- [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md)
- [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md)
- [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md)
- [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md)
- [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md)
- [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md)
- [8648.JP](https://longbridge.com/en/quote/8648.JP.md)

## Related News & Research

- [Equities Analysts Set Expectations for CRBU Q3 Earnings](https://longbridge.com/en/news/296219683.md)
- [Caribou Biosciences Q2 net loss narrows](https://longbridge.com/en/news/295849330.md)
- [Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft](https://longbridge.com/en/news/296352331.md)
- [20:00 ETAbelZeta Regains Global Rights of C-CAR039 (Prizlon-cel) and Receives FDA Clearance of IND Application in Large B-cell Lymphoma](https://longbridge.com/en/news/296036085.md)
- [Imugene shareholders back capital-raising resolutions at extraordinary meeting](https://longbridge.com/en/news/296287728.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**